Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

Does Stem Cell Therapy Work for Chronic Joint and Spine Pain?

Written by Dr. David Greene, MD, PhD, MBA on June 17, 2026

Table of Contents

If you live with chronic neck, back, knee, or shoulder pain, you’ve likely seen testimonials describing stem cell therapy as a way to avoid surgery and feel “brand new” again. These stories are compelling, but anecdote and evidence aren’t the same thing. This article looks at how stem cell therapy is intended to work, what current research actually supports, how it’s regulated, and what to ask before considering treatment — whether at a clinic such as R3 Stem Cell or elsewhere.

What Is Stem Cell Therapy for Joint and Spine Pain?

Stem cell therapy for musculoskeletal pain typically involves injecting mesenchymal stem cells (MSCs) into or near a damaged joint, tendon, or spinal structure to reduce pain and improve function. Sources vary:

Source

Description

Common Use

Bone marrow aspirate concentrate

Cells drawn from the patient’s own hip bone

Knee, hip, shoulder

Adipose (fat) tissue

Cells from the patient’s own fat tissue

Joints and soft tissue

Umbilical cord tissue (Wharton’s jelly)

Donor tissue from a scheduled, consented C-section

Joint, tendon, spine

Amniotic tissue/fluid

Donor tissue obtained with consent after childbirth

Joint and soft tissue

The first two are autologous (from and back to the same patient); the latter two are allogeneic (donor-sourced), and the choice between them carries different tradeoffs between autologous and allogeneic stem cell sourcing that providers weigh based on the condition being treated. For a deeper look at how each type of stem cell used in regenerative medicine is sourced and applied, providers typically tailor the choice to the specific condition being treated.

How Stem Cell Therapy Is Believed to Work

A common misconception is that injected cells directly regrow cartilage or disc tissue. Most current research instead points to a paracrine effect: MSCs release signaling molecules and exosomes that influence the surrounding tissue. Research shows MSCs can shift inflammatory macrophages toward an anti-inflammatory state through direct cell contact and the release of signaling factors and exosomes. These local paracrine signals develop through interaction between the injured tissue’s environment and the injected cells.

In simpler terms, the cells act more like chemical messengers that calm inflammation and support the body’s own repair process, rather than replacement parts. Substantial laboratory research has examined these mechanisms, but direct clinical applications in orthopedics remain limited, and further studies are needed before broader conclusions can be drawn.

What Does the Clinical Evidence Show?

Some small studies of mesenchymal stem cell injections for knee osteoarthritis report modest short-term symptom improvements, though certainty is low, and research products often differ from what’s offered commercially. Major medical groups have concluded that evidence is not yet strong enough to recommend stem cell injections for routine use in joint pain. Patients weighing whether to proceed may find it helpful to review a more complete risk-benefit analysis of mesenchymal stem cell therapy before making a decision.

Patients should also know that not every product marketed as containing stem cells delivers living cells by the time it reaches the patient. Independent studies have found no viable stem cells in several commercial amniotic products after processing, meaning marketing language can overstate what’s actually delivered. This doesn’t mean such products lack biological activity, but it does mean “stem cell” branding shouldn’t be taken at face value — a distinction worth understanding when comparing exosome therapy to traditional stem cell treatment, since the two are often confused in marketing materials.

The science is moving quickly. As of early 2026, roughly 224 clinical trials worldwide are investigating stem cell therapies for osteoarthritis, and a major Phase III trial backed by $140 million in funding was announced in January 2026. Results from trials at this scale are still years away from informing approved treatments or clinical guidelines.

FDA Regulation: What's Actually Approved

The FDA has not approved regenerative medicine products for any orthopedic condition, including osteoarthritis, tendonitis, disc disease, back pain, hip pain, knee pain, neck pain, or shoulder pain. As of 2026, the only fully FDA-approved stem cell products are blood-forming stem cells from umbilical cord blood, approved solely for blood disorders like leukemia — not orthopedic use. This regulatory gap is also why patients sometimes ask outright whether stem cell therapy is legal in the United States; the practice is legal under certain classifications, but that’s a distinct question from FDA approval.

Not all products are regulated identically. A “361 product” is minimally manipulated, intended for autologous use, and used in a way consistent with its original biological function. Products that don’t meet these criteria fall under the 351 pathway, requiring rigorous premarket approval as a drug or biologic. Patients curious about this distinction can review a more detailed explanation of FDA 351 versus 361 classification for cell and tissue products to understand how a given product is legally marketed. Parent’s Guide to Cord BloodParent’s Guide to Cord Blood

The regulatory landscape has shifted recently. In 2024, a federal appeals court affirmed the FDA’s authority to regulate unapproved stem cell mixtures derived from fat tissue and reinjected for conditions like knee osteoarthritis. In October 2025, the Supreme Court declined to revisit that ruling, confirming FDA authority over the industry after roughly seven years of litigation, even as the agency released new draft guidance in September 2025 outlining expedited review pathways for regenerative therapies. Some states, including Florida, Nevada, and Utah, have passed laws permitting certain stem cell therapies for orthopedic and pain management use, though federal regulation still takes precedence and state allowance doesn’t equate to FDA approval.

Common Conditions Patients Explore

Evidence strength varies considerably by diagnosis. Knee osteoarthritis has the largest body of supporting research, while other conditions, including chronic low back pain linked to disc degeneration, have a thinner evidence base even though treatment is commonly offered. Patients researching their own diagnosis may want to start by understanding the underlying causes of degenerative disc disease before evaluating whether a regenerative approach is appropriate for their specific case.

Risks to Consider

Any injection carries some risk of infection, allergic reaction, or inflammatory flare, and the FDA has issued consumer alerts following serious adverse events linked to unapproved stem cell products. Risk generally differs by cell source: a procedure using a patient’s own bone marrow carries a different profile than a heavily processed donor-tissue product, which is one reason understanding how the body responds to a stem cell injection before treatment matters.

Choosing a Provider

Useful questions before treatment include the cell source and whether it’s autologous or allogeneic, how the product is classified under FDA rules, what the clinic says about evidence and limitations (rather than guarantees), and the clinician’s specific training in regenerative orthopedic procedures. Patients comparing options may also find it useful to review general guidance on selecting a qualified regenerative medicine clinic before committing to treatment, since training and transparency vary widely across providers.

What Patients Often Report

Many patients describe meaningful improvements in comfort and mobility after treatment. In one account, a patient who had previously received stem cell treatment to his neck described it as feeling “brand new” several months later, after living with knee, back, and shoulder issues. Accounts like this are common in patient testimonials shared by regenerative medicine clinics, including R3 Stem Cell.

These stories matter, but individual outcomes vary, and testimonials aren’t controlled studies. The most responsible way to use one is as a single data point alongside the clinical and regulatory context above.

Alternatives Worth Discussing With Your Doctor

Stem cell therapy is rarely the first-line recommendation in conventional orthopedic care. Other options include physical therapy, anti-inflammatory medication, corticosteroid injections, activity modification, and surgery when conservative treatment fails. Platelet-rich plasma is another option some patients explore, and reviewing how PRP therapy works compared to stem cell injections can help clarify which approach, if any, fits a particular diagnosis. A conversation with an orthopedic specialist about your specific diagnosis and imaging findings is the right starting point.

Frequently Asked Questions

Is stem cell therapy FDA-approved for back, neck, knee, or shoulder pain?

No. The FDA has not approved any stem cell product for orthopedic conditions. Some products are legally marketed under a narrow exemption without proof of effectiveness for a specific condition, which is different from approval.

Does stem cell therapy regrow cartilage or disc tissue?

There is limited evidence of direct tissue regrowth. Most proposed benefit comes from anti-inflammatory and signaling effects.

Are umbilical cord or amniotic products the same as bone marrow stem cells?

No. They come from different sources, are regulated somewhat differently, and have different supporting research. Some donor-tissue products have tested as containing few or no living cells after processing.

Is it safe?

Risk varies by cell source and clinic. All injections carry some risk of infection or reaction, which should be discussed directly with a provider.

Contact Us

iPSCs are not the same as stem cell therapies currently in use. Mesenchymal stem cell (MSC) therapies — derived from umbilical cord tissue, bone marrow, or fat — are available now and work through anti-inflammatory signaling and immune modulation rather than direct tissue replacement.

It’s also worth understanding the difference between stem cell therapy and other regenerative approaches, and how regenerative medicine differs from traditional medicine.

R3 Stem Cell, operating across 80+ centers in eight countries, focuses on these established therapies while monitoring iPSC developments as the science matures. Learn more about what regenerative medicine is and the benefits of regenerative medicine.

Stem cell therapy for diabetes is not yet a standard of care in most countries and is generally considered investigational or complementary. Patients should review FDA regulations on cell therapies for context.

The shift in thinking began with a significant clinical study from Stanford University, published in Stroke in 2016. Researchers injected mesenchymal stem cells directly into the brains of chronic stroke patients through surgically drilled openings. The results were striking — patients who were years past their strokes showed measurable improvements in motor function, with no serious adverse events linked to the stem cells.

A follow-up phase 2b trial confirmed both the safety profile and the continued functional benefit.

The key finding was not just that patients improved — it was when they improved. These were patients well outside the traditional recovery window, which proved that the brain retains the capacity to respond to regenerative signals long after injury. To understand more about how stem cell therapy works at the biological level, it helps to look at the signaling and repair mechanisms that make these results possible.

Why Dr. Hector is "Passionate" About the Word "Natural"

DNA Mutations — The reprogramming process can introduce genetic mutations — either pre-existing or induced — that raise serious safety concerns before cells can be used in patients.

The FDA has not approved regenerative medicine products for any orthopedic condition, including osteoarthritis, tendonitis, disc disease, back pain, hip pain, knee pain, neck pain, or shoulder pain. As of 2026, the only fully FDA-approved stem cell products are blood-forming stem cells from umbilical cord blood, approved solely for blood disorders like leukemia — not orthopedic use. This regulatory gap is also why patients sometimes ask outright whether stem cell therapy is legal in the United States; the practice is legal under certain classifications, but that’s a distinct question from FDA approval.

Not all products are regulated identically. A “361 product” is minimally manipulated, intended for autologous use, and used in a way consistent with its original biological function. Products that don’t meet these criteria fall under the 351 pathway, requiring rigorous premarket approval as a drug or biologic. Patients curious about this distinction can review a more detailed explanation of FDA 351 versus 361 classification for cell and tissue products to understand how a given product is legally marketed. Parent’s Guide to Cord BloodParent’s Guide to Cord Blood

The regulatory landscape has shifted recently. In 2024, a federal appeals court affirmed the FDA’s authority to regulate unapproved stem cell mixtures derived from fat tissue and reinjected for conditions like knee osteoarthritis. In October 2025, the Supreme Court declined to revisit that ruling, confirming FDA authority over the industry after roughly seven years of litigation, even as the agency released new draft guidance in September 2025 outlining expedited review pathways for regenerative therapies. Some states, including Florida, Nevada, and Utah, have passed laws permitting certain stem cell therapies for orthopedic and pain management use, though federal regulation still takes precedence and state allowance doesn’t equate to FDA approval.

Consent alone is not sufficient. Donor mothers also undergo comprehensive medical screening, which typically includes:

What Does the Bioethics Community Say?

Many patients describe meaningful improvements in comfort and mobility after treatment. In one account, a patient who had previously received stem cell treatment to his neck described it as feeling “brand new” several months later, after living with knee, back, and shoulder issues. Accounts like this are common in patient testimonials shared by regenerative medicine clinics, including R3 Stem Cell.

These stories matter, but individual outcomes vary, and testimonials aren’t controlled studies. The most responsible way to use one is as a single data point alongside the clinical and regulatory context above.